GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » Insider Ownership

AP Biosciences (ROCO:6945) Insider Ownership : 0.00 % (As of Mar. 26, 2025)


View and export this data going back to 2023. Start your Free Trial

What is AP Biosciences Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AP Biosciences's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AP Biosciences's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AP Biosciences's Float Percentage Of Total Shares Outstanding is 0.00%.


AP Biosciences Insider Ownership Historical Data

The historical data trend for AP Biosciences's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AP Biosciences Insider Ownership Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Insider Ownership
- - - -

AP Biosciences Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Insider Ownership Get a 7-Day Free Trial - - - - -

AP Biosciences Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


AP Biosciences Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.

AP Biosciences Headlines

No Headlines